News
Video
Author(s):
Dr Gligorov underscores the significance of real-world data in France supporting the effectiveness of tucatinib and trastuzumab in combination for patients with heavily pretreated HER2+ metastatic breast cancer, with notable benefits even in cases with brain metastasis.